Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 197 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: desensitization Clear all
Terminated Phase 2 Interventional Results available

Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant

NCT01025193
View directory record Official record
Conditions
Desensitization
Interventions
Belimumab
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 18, 2026, 1:29 PM EDT
Suspended Not applicable Interventional

Augmenting Virtual Reality Exposure Therapy for Acrophobia

NCT03917433
View directory record Official record
Conditions
Specific Phobia, Anxiety Disorders, Fear of Heights, Acrophobia
Interventions
Virtual Reality Exposure Therapy, Tactile Feedback, Point-based Rewards
Behavioral
Lead sponsor
University of Nevada, Reno
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 18, 2026, 1:29 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer

NCT06620029
View directory record Official record
Conditions
Ovarian Neoplasms, Endometrial Cancer, Endometrial Neoplasm
Interventions
BMX-001, Paclitaxel (Taxol)
Drug
Lead sponsor
BioMimetix JV, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 18, 2026, 1:29 PM EDT
Completed Phase 2 Interventional Results available

The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery

NCT02103270
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut Protein 4,000mg, Oat Flour, Peanut Protein 300 mg
Drug
Lead sponsor
Stanford University
Other
Eligibility
7 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 18, 2026, 1:29 PM EDT
Completed Phase 2 Interventional

3MDR to Treat PTSD With mTBI (3MDR)

NCT03796936
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Traumatic Brain Injury
Interventions
Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR) Therapy
Behavioral
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 18, 2026, 1:29 PM EDT
Not listed Not applicable Interventional

BFR DISTRAD: Blood Flow Restricted Training During Rehabilitation Following Distal Radius Fracture Repair

NCT02482727
View directory record Official record
Conditions
Distal Radius Fracture, Rehabilitation
Interventions
occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)
Device
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 18, 2026, 1:29 PM EDT
Recruiting Not applicable Interventional

Reward Processing and Exposure Therapy for Social Anxiety Disorder

NCT06776991
View directory record Official record
Conditions
Social Anxiety Disorder (Social Phobia), Public Speaking Anxiety, Anhedonia, ANXIETY DISORDERS (or Anxiety and Phobic Neuroses), Phobic Disorders
Interventions
Positive Affect Treatment - Behavioral (PAT-B), Relaxation Treatment, Exposure Therapy
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 18, 2026, 1:29 PM EDT
Recruiting Early Phase 1 Interventional

Piloting Virtual Reality Environments to Treat PTSD in Healthcare Workers

NCT04887116
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Virtual Reality Exposure Therapy
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 18, 2026, 1:29 PM EDT
Completed Phase 2Phase 3 Interventional Results available

D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD

NCT00356278
View directory record Official record
Conditions
Stress Disorder, Post Traumatic
Interventions
D-Cycloserine, Alprazolam, Virtual Reality Exposure Therapy, Placebo
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2016 · Synced Oct 18, 2026, 1:29 PM EDT
Terminated Not applicable Interventional

Embodied Virtual Reality Therapy for Functional Neurological Symptom/ Conversion Disorder

NCT02764476
View directory record Official record
Conditions
Conversion Disorder, Psychogenic Movement Disorder, Functional Movement Disorder, Functional Neurological Disorder, Non-epileptic Seizures
Interventions
Embodied Virtual Reality Therapy, Virtual reality
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 18, 2026, 1:29 PM EDT
Not listed Not applicable Interventional

BFR DISTRAD NON OP: Blood Flow Restricted Training During Rehabilitation Following Distal Radius Fracture

NCT03056950
View directory record Official record
Conditions
Distal Radius Fracture, Rehabilitation
Interventions
DELFI PTS ii portable tourniquet
Device
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Oct 18, 2026, 1:29 PM EDT
Completed Phase 2 Interventional Results available

Combining Antidepressant Medication and Psychotherapy for Insomnia to Improve Depression Outcome

NCT00149825
View directory record Official record
Conditions
Major Depressive Disorder, Insomnia
Interventions
Escitalopram, CBTI, CTRL
Drug · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 18, 2026, 1:29 PM EDT
Terminated No phase listed Observational

An In-vitro Standardization of B Cell Elispot Assays

NCT01334281
View directory record Official record
Conditions
Transplant Sensitization, Panel Reactive Antibody, Sensitization to HLA Antigens
Interventions
Blood Draw
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 18, 2026, 1:29 PM EDT
Not listed No phase listed Observational

Intensive Therapy Archival Research

NCT03271398
View directory record Official record
Conditions
Trauma, Psychological
Interventions
EMDR, PC
Behavioral
Lead sponsor
Trauma Institute & Child Trauma Institute
Other
Eligibility
Not listed
Enrollment
1,200 participants
Timeline
2017 – 2022
U.S. locations
1
States / cities
Northampton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Oct 18, 2026, 1:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance

NCT01373242
View directory record Official record
Conditions
Peanut Hypersensitivity, Food Hypersensitivity, Food Allergy, Peanut Allergy
Interventions
Liquid peanut extract (Peanut SLIT)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 12 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 18, 2026, 1:29 PM EDT
Completed Phase 1 Interventional

A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation

NCT02586051
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Obinutuzumab, Intravenous Immunoglobulin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 18, 2026, 1:29 PM EDT
Completed Not applicable Interventional

Immunotherapy for Peanut Allergy

NCT00429429
View directory record Official record
Conditions
Allergy
Interventions
Sublingual immunotherapy
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Years to 35 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Oct 18, 2026, 1:29 PM EDT
Completed Phase 3 Interventional Results available

AR101 Real-World Open-Label Extension Study

NCT03337542
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 17 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
55
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 18, 2026, 1:29 PM EDT
Completed Phase 1 Interventional

Desensitization of Renal Transplant Candidates

NCT00298883
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Transplantation
Interventions
Myfortic
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Oct 18, 2026, 1:29 PM EDT
Completed Not applicable Interventional

Desensitization to Reduce Oral Hypersensitivity and Improve Intake for Children With Feeding Disorders

NCT03739047
View directory record Official record
Conditions
Feeding Disorder
Interventions
Desensitization with flipped spoon, flipped spoon
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
10 Months to 10 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 18, 2026, 1:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation

NCT01594424
View directory record Official record
Conditions
End Stage Renal Disease (ESRD)
Interventions
Tocilizumab, Intravenous Immunoglobulin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Oct 18, 2026, 1:29 PM EDT
Completed Phase 2 Interventional Results available

OIT and Xolair® (Omalizumab) in Cow's Milk Allergy

NCT01157117
View directory record Official record
Conditions
Milk Allergy
Interventions
Placebo for omalizumab, Omalizumab, Milk powder
Biological · Drug
Lead sponsor
Hugh A Sampson, MD
Other
Eligibility
7 Years to 35 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Stanford, California • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 18, 2026, 1:29 PM EDT
Completed Not applicable Interventional Results available

Efficacy and Neural Mediators of Response to Trauma Management Therapy for PTSD

NCT03449576
View directory record Official record
Conditions
PTSD
Interventions
Trauma Management Therapy, Exposure Therapy with Psychotherapy group
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Salem, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 18, 2026, 1:29 PM EDT
Completed Phase 1Phase 2 Interventional

Novel Desensitization Kidney Transplantation

NCT05345717
View directory record Official record
Conditions
Kidney Transplantation, End Stage Kidney Disease (ESRD)
Interventions
Belatacept Injection
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 18, 2026, 1:29 PM EDT